APOE4

Thinning of brain region may signal dementia risk 5-10 years before symptoms

Retrieved on: 
Wednesday, January 24, 2024

SAN ANTONIO, Jan. 23, 2024 /PRNewswire-PRWeb/ -- A ribbon of brain tissue called cortical gray matter grows thinner in people who go on to develop dementia, and this appears to be an accurate biomarker of the disease five to 10 years before symptoms appear, researchers from The University of Texas Health Science Center at San Antonio (also called UT Health San Antonio) reported.

Key Points: 
  • Researchers at The University of Texas Health Science Center at San Antonio discover a possible biomarker indicating dementia risk well in advance.
  • The California volunteers included 44% representation of Black and Hispanic participants, whereas the Massachusetts cohort was predominantly non-Hispanic white.
  • While dementias can affect different brain regions, Alzheimer's disease and frontotemporal dementia impact the cortex, and Alzheimer's is the most common type of dementia.
  • "The relationship between thinning and dementia risk behaved the same way in different races and ethnic groups."

Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer and Strengthens Commercial Organization with New Executive Appointments to Lead Planned U.S. Commercial Launch of Oral ALZ-801/Valiltramiprosate in 2025

Retrieved on: 
Tuesday, December 5, 2023

“Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.

Key Points: 
  • “Alzheon’s novel therapeutic approach has an opportunity to transform the standard of care and improve access to treatment for all Alzheimer’s patients.
  • He has more than 20 years of commercial launch, sales, market access, and leadership experience in the biopharmaceutical industry.
  • Previously, Mr. Greene held commercial and executive roles at Janssen, Otsuka, and Biogen, with over a dozen launches in CNS disorders and Alzheimer’s.
  • Having these strong leaders further enhances our ability to establish critical partnerships and patient advocacy programs to support a successful commercial launch in 2025.”

Alzheon CEO Dr. Martin Tolar to Discuss Positive Results from Phase 2 Biomarker Study and Upcoming Readout from Pivotal APOLLOE4 Phase 3 Study Evaluating Oral ALZ-801/Valiltramiprosate at Truist Securities BioPharma Symposium

Retrieved on: 
Tuesday, October 31, 2023

Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.

Key Points: 
  • Alzheon executive management will be available to meet with qualified members of the investor community who are registered to attend the conference.
  • This panel will be moderated by Truist analyst, Robyn Karnauskas, PhD.
  • “Alzheon’s simple oral tablet has the potential to address a large unmet need from both an access and treatment perspective.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure neurotoxic amyloid oligomers in CSF.

uMETHOD Health Highlights Factors Contributing to Cognitive Decline for Alzheimer's Awareness Month

Retrieved on: 
Wednesday, November 1, 2023

RALEIGH, N.C., Nov. 1, 2023 /PRNewswire/ -- uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, is taking an active role in drawing attention to the various factors that can contribute to the development of Alzheimer's disease. As a part of its efforts during Alzheimer's Awareness Month, uMETHOD is educating the public on the risk factors associated with Alzheimer's and the importance of early intervention.

Key Points: 
  • As a part of its efforts during Alzheimer's Awareness Month, uMETHOD is educating the public on the risk factors associated with Alzheimer's and the importance of early intervention.
  • Alzheimer's disease is a progressive brain disorder that affects 5.7 million U.S. adults, with many more in preceding stages of decline.
  • Through RestoreU , uMETHOD harnesses the power of analytics and data to help physicians close care gaps for patients with cognitive decline.
  • Join us on Facebook , Twitter and LinkedIn this month as we share more information about these contributing factors and how to boost your brain health.

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at 16th Annual Clinical Trials in Alzheimer’s Disease Conference

Retrieved on: 
Tuesday, October 17, 2023

We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral anti-amyloid disease modifying therapy for Alzheimer’s disease,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.

Key Points: 
  • We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral anti-amyloid disease modifying therapy for Alzheimer’s disease,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • “Our efficacy data combined with a favorable safety profile with no events of vasogenic edema underscore the differentiated clinical profile of ALZ-801 tablet.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • In addition, Alzheon is collaborating with the Czech Institute of Organic Chemistry & Biochemistry (IOCB) to develop an assay to measure the neurotoxic amyloid oligomers in CSF.

NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer’s Disease

Retrieved on: 
Tuesday, September 26, 2023

Deletion of APOE has been demonstrated to limit disease in multiple AD models.

Key Points: 
  • Deletion of APOE has been demonstrated to limit disease in multiple AD models.
  • In preclinical AD animal models, NC181 has demonstrated differentiation from amyloid targeted therapies.
  • Key findings from the study include:
    NC181 binds to amyloid associated ApoE4, resulting in amyloid clearance and prevention of amyloid deposition in mice.
  • Additional studies to characterize NC181 as a potential therapeutic for AD and CAA are ongoing.

Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate at Singularity Conference, Goldman Sachs Alzheimer’s Disease Day, and BIO Investor Forum

Retrieved on: 
Tuesday, September 26, 2023

Event: BIO Investor Forum , independent biotech industry event dedicated to showcasing leading drug development programs for partnering and venture investments.

Key Points: 
  • Event: BIO Investor Forum , independent biotech industry event dedicated to showcasing leading drug development programs for partnering and venture investments.
  • The treatment landscape for Alzheimer’s disease is beginning to take shape and Alzheon’s simplified approach has an opportunity to transform the standard of care and enhance access for patients with Alzheimer’s disease.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal 78-week APOLLOE4 Phase 3 trial , which is now fully enrolled and topline data is expected in the third quarter of 2024.

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

Retrieved on: 
Wednesday, September 13, 2023

“We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral disease modifying therapy for Alzheimer’s disease.

Key Points: 
  • “We are pleased with the growing body of evidence that supports ALZ-801’s potential as the first oral disease modifying therapy for Alzheimer’s disease.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • In November 2022, Alzheon reported positive study results from a pre-specified analysis following 52 weeks of treatment with ALZ-801.
  • An ongoing long-term extension of the trial evaluates ALZ-801 for an additional 52 weeks of treatment for a total of 156 weeks.

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at AAIC in Amsterdam

Retrieved on: 
Tuesday, July 11, 2023

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in the third quarter of 2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”

Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston

Retrieved on: 
Tuesday, April 18, 2023

ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.

Key Points: 
  • ALZ-801 (valiltramiprosate) is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of early AD.
  • In mechanism-of-action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid (Aβ) oligomers at the Phase 3 clinical dose.
  • This population is the focus of Alzheon’s pivotal Phase 3 APOLLOE4 trial , which is now fully enrolled and will be completed in mid-2024.
  • We look forward to communicating the final 24-month data from our Phase 2 study later in 2023.”